GLP-1 Receptor Agonists for PCOS

PCOS pathophysiology and weight

PCOS is heterogeneous. The Rotterdam criteria require at least 2 of 3: hyperandrogenism (clinical or biochemical), ovulatory dysfunction, and polycystic ovary morphology on ultrasound. Approximately 50% to 70% of PCOS patients have insulin resistance, and 40% to 70% have overweight or obesity. The relationship between insulin resistance, hyperandrogenism, and ovulatory dysfunction is bidirectional¹.

Weight loss in the range of 5% to 10% has been demonstrated to improve menstrual regularity, restore ovulation, reduce hyperandrogenism, and improve metabolic markers in overweight PCOS patients. This effect is independent of medication mechanism: lifestyle-induced weight loss, bariatric surgery weight loss, and pharmacotherapy weight loss all produce these benefits in proportion to magnitude.

Trial data for GLP-1 in PCOS

Three randomized trials have specifically evaluated GLP-1 agonists in PCOS. A 2020 trial of liraglutide 3.0 mg versus placebo in 72 women with PCOS and BMI > 25 kg/m² showed 5.2% body weight loss versus 0.2% with placebo at 32 weeks, with significant improvements in menstrual frequency and free testosterone levels².

A 2022 trial of semaglutide 1 mg versus placebo in 92 women with PCOS and obesity showed 9.4% body weight loss at 28 weeks, with substantially improved ovulation rates (38% versus 5% achieving regular ovulation) and reduced total testosterone³.

A 2024 open-label study of tirzepatide in 56 women with PCOS reported 16% mean weight loss at 24 weeks with improvements in menstrual regularity and free testosterone⁴. Randomized data for tirzepatide in PCOS specifically are pending; the SURMOUNT trials enrolled women with obesity broadly but did not stratify by PCOS status.

Mechanism — beyond weight loss

GLP-1 receptor agonists appear to produce metabolic benefits in PCOS through both weight-loss-dependent and weight-loss-independent pathways. Reduction in hyperinsulinemia (independent of weight loss) decreases ovarian androgen production, improves SHBG levels, and reduces free testosterone. GLP-1 receptors are expressed on ovarian theca cells, and direct GLP-1 receptor activation may affect ovarian steroidogenesis independent of insulin⁵.

GLP-1 effects on the HPA axis, sympathetic nervous system, and inflammatory markers may also contribute to the PCOS-specific response. Studies that have compared GLP-1 to metformin (the most established PCOS pharmacotherapy) have shown greater weight loss with GLP-1 and similar improvements in androgen markers.

Fertility considerations

GLP-1 receptor agonists are NOT recommended for use during pregnancy or in patients actively trying to conceive. The FDA labeling specifies discontinuation at least 2 months before planned pregnancy for semaglutide, given its long half-life. Tirzepatide labeling specifies discontinuation at least 4 weeks before planned pregnancy.

GLP-1 therapy paradoxically improves fertility in PCOS by restoring ovulation. Patients should be counseled that pregnancy may occur unexpectedly once ovulation resumes, particularly during the 6-month window after starting therapy. Adequate contraception is essential. The combination of GLP-1 and oral contraceptives is well-tolerated, although some clinicians prefer barrier methods or IUDs for added reliability given GLP-1's effects on gastric emptying that could theoretically reduce oral contraceptive absorption.

Adolescent PCOS

Adolescent PCOS (diagnosed before age 18) is a distinct clinical entity with different diagnostic criteria and treatment considerations. GLP-1 receptor agonists are FDA-approved for adolescents aged 12 and older for weight management (Wegovy) or type 2 diabetes (Ozempic, Mounjaro). Specific PCOS data in adolescents are limited but extrapolation from adult evidence is reasonable.

Bone health is a relevant consideration in adolescent GLP-1 use. Rapid weight loss may transiently affect bone density; adequate calcium and vitamin D intake should be ensured. Adolescent patients on GLP-1 therapy should be monitored more closely than adults for growth, mood, and eating-disorder symptoms; the screen for disordered eating is particularly important in this population.

Clinical recommendations

For overweight or obese PCOS patients who have not achieved adequate weight loss with lifestyle modification alone, GLP-1 receptor agonists are a reasonable second-line option (typically after a metformin trial). Choice between semaglutide and tirzepatide is generally individualized based on insurance coverage, cost, and patient preference.

Treatment goals should be discussed clearly: weight loss, metabolic improvement, menstrual regularity, and (if applicable) preparation for pregnancy. Patients planning pregnancy should discontinue GLP-1 therapy 2 to 8 weeks before attempting conception (timing depends on the specific molecule); other PCOS-friendly pharmacotherapies (metformin) can be continued through preconception and pregnancy in most cases.

Monitoring during GLP-1 therapy in PCOS should include menstrual cycle tracking, periodic free testosterone and SHBG measurement (typically at baseline and at 3 to 6 months), HbA1c (especially in patients with insulin resistance), and standard weight and blood pressure follow-up. Ovulation tracking is appropriate for patients prepared for pregnancy.

Related editorial coverage

• Semaglutide peptide profile
• Tirzepatide peptide profile
• Weight-loss therapeutics category

Frequently asked questions

Can semaglutide help with PCOS?

Yes. Semaglutide has demonstrated significant weight loss, improved ovulation rates, and reduced androgen levels in randomized trials of women with PCOS³. It is used off-label for PCOS in addition to FDA-approved indications. Clinical evidence is strongest for overweight/obese PCOS patients who have not responded to metformin or lifestyle intervention alone.

Can you get pregnant on GLP-1 medications?

GLP-1 medications can paradoxically improve fertility in PCOS by restoring ovulation. However, they are NOT recommended during pregnancy. FDA labeling specifies discontinuation 2 months before planned pregnancy for semaglutide and 4 weeks for tirzepatide. Adequate contraception is essential during therapy. Patients planning pregnancy should discontinue GLP-1 before attempting conception.

Is GLP-1 better than metformin for PCOS?

GLP-1 receptor agonists produce greater weight loss than metformin and similar or greater improvements in metabolic and androgenic markers in PCOS. However, metformin has decades of safety data, no risk of GI side effects of the same magnitude, and can be continued through pregnancy. The two are often used sequentially or in combination depending on patient response and goals.

Does insurance cover GLP-1 for PCOS?

Insurance coverage for off-label PCOS use is variable. Coverage is more common when the patient also meets approved indications (type 2 diabetes for Ozempic/Mounjaro, BMI ≥30 or ≥27 with comorbidity for Wegovy/Zepbound). Documentation of failed metformin trial and lifestyle intervention may strengthen prior authorization requests. Cash-pay compounded options are widely available at $145 to $400 per month.